You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Developing a novel adjuvant system for therapeutic vaccines against lung cancer

    SBC: FasCure Therapeutics LLC            Topic: 102

    DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. A Novel Biologic for the Treatment of Hypogonadism

    SBC: JangoBio, LLC            Topic: N

    DESCRIPTION provided by applicant Male hypogonadism results from failure of the testes to produce sufficient sex hormones Aging is the greatest cause of primary hypogonadism otherwise known as testosterone deficiency syndrome TDS and in the United States affects million men while undiagnosed cases of TDS are upwards of million men TDS adversely affects male health and has been lin ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Target Identification for Novel Small Molecule Therapeutic for Alzheimer's disease

    SBC: CoPlex Therapeutics, LLC            Topic: NIA

    ABSTRACT Traditional approaches to drug development for Alzheimer s disease are becoming increasingly expensive and in many cases disappointingly unsuccessful Based on preliminary in vitro and in vivo studies we have identified a novel small molecule methyl dimethyl oxo dihydrobenzo c naphthyridine carboxylate UK that significantly decreases A production and pro in ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Streamlining HTS Assay Development through Direct Selection of Structure-Switching Aptamers

    SBC: Bellbrook Labs, LLC            Topic: 300

    Project Summary Abstract High throughput screening HTS is a powerful method for the discovery of new drug leads for target enzymes In HTS assays the activity of the target enzyme is often evaluated by quantifying a small molecule or cofactor that is produced or consumed by the enzyme While antibodies are a mainstay of small molecule detection as says they do have severe limitations which a ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Cryopreservation and Cloning of Somatic Cells to Preserve Zebrafish Germplasm

    SBC: FreezeBack, LLC            Topic: OD

    DESCRIPTION provided by applicant Freezing whole zebrafish embryos in order to later recover live fish is not currently possible Researchers seeking to preserve zebrafish genetic lines are presently limited to the options of storing frozen sperm in sperm banks or maintaining the fish alive These limitations increase costs and hinder the efficient dissemination of superior wild type and mutan ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Novel Nanosecond Laser and Ultrasound to Selectively Treat Eye Blood Vessels

    SBC: PHOTOSONOX LLC            Topic: NEI

    ABSTRACT / PROJECT SUMMARY Wet age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed world. Anti-VEGF therapy is currently the gold standard for wet AMD treatment. However, up to 50% of patients in the long term have a suboptimal response to anti-VEGF therapy. A better alternative method for treatment of AMD is urgently needed. We have recently inve ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Stress forces huESC differentiation; confirmation as an accurate DevTox HTS

    SBC: REPRODUCTIVE STRESS MEASUREMENT MECHANISMS & MANAGEMENT CORP            Topic: R

    EXECUTIVE SUMMARY - huESC HTS2 - human Toxic stress effects in 1st trimester pregnancy leads to $10s of billions of US health care costs/year and is a significant part of the $2.5-4B/year US Developmental and Reproductive Technology (DART industry. Current DART techniques use slow, expensive pregnant rodent tests, or tests of embryonic stem cells (ESCs) that are cultured to lose “stemness” and ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Determination of circulation factors that mediate the health benefits of exercise in mitochondrial aging

    SBC: CYTEGEN CORP            Topic: NIA

    Project Summary/Abstract: This proposal seeks to test the hypothesis that endurance exercise stimulates the release of circulating factors that improve mitochondrial fitness. CyteGen’s goal is to identify these endogenous factors and engineer them to treat diseases in which mitochondrial dysfunction is central. These diseases include neurodegenerative and other diseases associated with aging, as ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. An augmented reality platform to reduce post-operative and chronic opioid use in pediatric cancer

    SBC: ALTALITY, INC.            Topic: NIDA

    PROJECT SUMMARY/ABSTRACT Pediatric opioid use is a public health crisis. In children, prescription opioids are the primary source of non- medical abuse as well as opioid-associated hospitalizations and deaths. Early opioid use in childhood is a known “gateway” to adulthood dependence and substance abuse disorders. Despite years of research, opioids remain the most commonly prescribed pain medi ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Cerenkov Multi-Spectral Imaging (CMSI) for Adaptation and Real-Time Imaging in Radiotherapy

    SBC: ENDECTRA LLC            Topic: 102

    PROJECT SUMMARY Understanding of tumor molecular characteristics during a course of radiotherapy (RT) treatment is crucial to assess the efficacy of the treatment and adapt radiation dosage to optimize outcomes. Unfortunately, this cannot be routinely achieved by current diagnostic nuclear imaging modalities due to complex logistics and prohibitive costs. Alternatively, Cerenkov Emission (CE) is a ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government